Alemtuzumab Following Natalizumab in Highly Active Paediatric-Onset Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
doi 10.1177/2055217319875471
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Cladribine for Highly Active Relapsing Multiple Sclerosis

Prescriber
Pharmacology
2018English

JC Virus Persistence Following Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients Treated With Natalizumab

Annals of Neurology
Neurology
2010English

Immune Competence After Alemtuzumab Treatment of Multiple Sclerosis

Neurology
Neurology
2013English

Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England

Journal of Medical Economics
Health Policy
2018English

Evolution of MRI Appearances Due to Progressive Multifocal Leucoencephalopathy Following Natalizumab Treatment for Multiple Sclerosis

BMJ Case Reports
Medicine
2015English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Periventricular Magnetisation Transfer Ratio Abnormalities in Multiple Sclerosis Improve After Alemtuzumab

Multiple Sclerosis
Neurology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy